1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Haller DG, Catalano PJ, Macdonald JS,
O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study
of fluorouracil, leucovorin, and levamisole in high-risk stage II
and III colon cancer: final report of Intergroup 0089. J Clin
Oncol. 23:8671–8678. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lembersky BC, Wieand HS, Petrelli NJ,
O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall
ME, Jacobs AD, et al: Oral uracil and tegafur plus leucovorin
compared with intravenous fluorouracil and leucovorin in stage II
and III carcinoma of the colon: results from National Surgical
Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol.
24:2059–2064. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al Multicenter International Study of
Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of
Colon Cancer (MOSAIC) Investigators, : Oxaliplatin, fluorouracil,
and leucovorin as adjuvant treatment for colon cancer. N Engl J
Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Gramont A, Boni C, Navarro M, Tabernero J,
Hickish T, Topham C, Bonetti A, Clingan P, Marceau-Suissa J,
Lorenzato C and André T: Oxaliplatin/5FU/LV in the adjuvant
treatment of stage II and stage III colon cancer: efficacy results
with a median follow-up of 4 years. J Clin Oncol. 23 (Suppl
16):35012005. View Article : Google Scholar
|
7
|
Kuebler JP, Wieand HS, O'Connell MJ, Smith
RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE,
Atkins JN, et al: Oxaliplatin combined with weekly bolus
fluorouracil and leucovorin as surgical adjuvant chemotherapy for
stage II and III colon cancer: results from NSABP C-07. J Clin
Oncol. 25:2198–2204. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Maenhaut C, Dumont JE, Roger PP and van
Staveren WC: Cancer stem cells: a reality, a myth, a fuzzy concept
or a misnomer? An analysis. Carcinogenesis. 31:149–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
9
|
O'Brien CA, Kreso A and Jamieson CH:
Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120.
2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: the cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Dave B and Chang J: Treatment resistance
in stem cells and breast cancer. J Mammary Gland Biol Neoplasia.
14:79–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Crea F, Danesi R and Farrar WL: Cancer
stem cell epigenetics and chemoresistance. Epigenomics. 1:63–79.
2009. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: The potential of nanomedicine. Nanomedicine
(Lond). 7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Fábián A, Barok M, Vereb G and Szöllosi J:
Die hard: Are cancer stem cells the Bruce Willises of tumor
biology? Cytometry A. 75:67–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Moitra K, Lou H and Dean M: Multidrug
efflux pumps and cancer stem cells: Insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther.
89:491–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shervington A and Lu C: Expression of
multidrug resistance genes in normal and cancer stem cells. Cancer
Invest. 26:535–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gillet JP, Efferth T and Remacle J:
Chemotherapy-induced resistance by ATP-binding cassette transporter
genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
|
19
|
Li W, Zhang H, Assaraf YG, Zhao K, Xu X,
Xie J, Yang DH and Chen ZS: Overcoming ABC transporter-mediated
multidrug resistance: molecular mechanisms and novel therapeutic
drug strategies. Drug Resist Updat. 27:14–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Artells R, Moreno I, Díaz T, Martínez F,
Gel B, Navarro A, Ibeas R, Moreno J and Monzó M: Tumour CD133 mRNA
expression and clinical outcome in surgically resected colorectal
cancer patients. Eur J Cancer. 46:642–649. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kahlert C, Gaitzsch E, Steinert G, Mogler
C, Herpel E, Hoffmeister M, Jansen L, Benner A, Brenner H,
Chang-Claude J, et al: Expression analysis of aldehyde
dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in
association with prognosis and response to chemotherapy. Ann Surg
Oncol. 19:4193–4201. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Liu Z, Dai W, Jiang L and Cheng Y:
Over-expression of LGR5 correlates with poor survival of colon
cancer in mice as well as in patients. Neoplasma. 61:177–185. 2014.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Wang X, Xia B, Liang Y, Peng L, Wang Z,
Zhuo J, Wang W and Jiang B: Membranous ABCG2 expression in
colorectal cancer independently correlates with shortened patient
survival. Cancer Biomark. 13:81–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hlavata I, Mohelnikova-Duchonova B,
Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O,
Holubec L, Treska V, et al: The role of ABC transporters in
progression and clinical outcome of colorectal cancer. Mutagenesis.
27:187–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Mirakhorli M, Shayanfar N, Rahman SA,
Rosli R, Abdullah S and Khoshzaban A: Lack of association between
expression of MRP2 and early relapse of colorectal cancer in
patients receiving FOLFOX-4 chemotherapy. Oncol Lett. 4:893–897.
2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Saigusa S, Tanaka K, Toiyama Y, Yokoe T,
Okugawa Y, Ioue Y, Miki C and Kusunoki M: Correlation of CD133,
OCT4, and SOX2 in rectal cancer and their association with distant
recurrence after chemoradiotherapy. Ann Surg Oncol. 16:3488–3498.
2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y,
Yang TS, Chen JS, Tang RP, Chen SJ and Chen HC: Overexpression of
Lgr5 correlates with resistance to 5-FU-based chemotherapy in
colorectal cancer. Int J Colorectal Dis. 28:1535–1546. 2013.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Hongo K, Tanaka J, Tsuno NH, Kawai K,
Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, et
al: CD133(−) cells, derived from a single human colon cancer cell
line, are more resistant to 5-fluorouracil (FU) than CD133(+)
cells, dependent on the β1-integrin signaling. J Surg Res.
175:278–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Liu YS, Hsu HC, Tseng KC, Chen HC and Chen
SJ: Lgr5 promotes cancer stemness and confers chemoresistance
through ABCB1 in colorectal cancer. Biomed Pharmacother.
67:791–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yu Z, Zhang C, Wang H, Xing J, Gong H, Yu
E, Zhang W, Zhang X, Cao G and Fu C: Multidrug
resistance-associated protein 3 confers resistance to
chemoradiotherapy for rectal cancer by regulating reactive oxygen
species and caspase-3-dependent apoptotic pathway. Cancer Lett.
353:182–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lin PC, Lin HH, Lin JK, Lin CC, Yang SH,
Li AF, Chen WS and Chang SC: Expression of ABCG2 associated with
tumor response in metastatic colorectal cancer patients receiving
first-line FOLFOX therapy-preliminary evidence. Int J Biol Markers.
28:182–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Shima H, Kutomi G, Satomi F, Maeda H,
Hirohashi Y, Hasegawa T, Mori M, Torigoe T and Takemasa I: SOX2 and
ALDH1 as predictors of operable breast cancer. Anticancer Res.
36:2945–2953. 2016.PubMed/NCBI
|
33
|
Chen J, Xia Q, Jiang B, Chang W, Yuan W,
Ma Z, Liu Z and Shu X: Prognostic value of cancer stem cell marker
ALDH1 expression in colorectal cancer: a systematic review and
meta-analysis. PLoS One. 10:e01451642015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Yoshihama R, Yamaguchi K, Imajyo I, Mine
M, Hiyake N, Akimoto N, Kobayashi Y, Chigita S, Kumamaru W,
Kiyoshima T, et al: Expression levels of SOX2, KLF4 and brachyury
transcription factors are associated with metastasis and poor
prognosis in oral squamous cell carcinoma. Oncol Lett.
11:1435–1446. 2016. View Article : Google Scholar : PubMed/NCBI
|
35
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th. Springer; New
York: 2017, View Article : Google Scholar
|
36
|
U.S. Department of Health Human Services,
National Institutes of Health, National Cancer Institute, . Comom
Terminology Criteria for Adverse Events (CTCAE). Version 4.0, 2009.
https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5×7.pdfMay
28–2009
|
37
|
Huang EH and Wicha MS: Colon cancer stem
cells: Implications for prevention and therapy. Trends Mol Med.
14:503–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
38
|
Yoshida A, Rzhetsky A, Hsu LC and Chang C:
Human aldehyde dehydrogenase gene family. Eur J Biochem.
251:549–557. 1998. View Article : Google Scholar : PubMed/NCBI
|
39
|
Sophos NA and Vasiliou V: Aldehyde
dehydrogenase gene superfamily: the 2002 update. Chem Biol
Interact. 143-144:5–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
40
|
Yamanoi K, Fukuma M, Uchida H, Kushima R,
Yamazaki K, Katai H, Kanai Y and Sakamoto M: Overexpression of
leucine-rich repeat-containing G protein-coupled receptor 5 in
gastric cancer. Pathol Int. 63:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
41
|
Avoranta ST, Korkeila EA, Ristamäki RH,
Syrjänen KJ, Carpén OM, Pyrhönen SO and Sundström JT: ALDH1
expression indicates chemotherapy resistance and poor outcome in
node-negative rectal cancer. Hum Pathol. 44:966–974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Saigusa S, Inoue Y, Tanaka K, Toiyama Y,
Kawamura M, Okugawa Y, Okigami M, Hiro J, Uchida K, Mohri Y, et al:
Significant correlation between LKB1 and LGR5 gene expression and
the association with poor recurrence-free survival in rectal cancer
after preoperative chemoradiotherapy. J Cancer Res Clin Oncol.
139:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
44
|
Tomita H, Tanaka K, Tanaka T and Hara A:
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget.
7:11018–11032. 2016. View Article : Google Scholar : PubMed/NCBI
|
45
|
Chang B, Liu G, Xue F, Rosen DG, Xiao L,
Wang X and Liu J: ALDH1 expression correlates with favorable
prognosis in ovarian cancers. Modern pathology: An official journal
of the United States and Canadian Academy of Pathology. Inc.
22:817–823. 2009.
|
46
|
Boumahdi S, Driessens G, Lapouge G, Rorive
S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E,
et al: SOX2 controls tumour initiation and cancer stem-cell
functions in squamous-cell carcinoma. Nature. 511:246–250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Zhu F, Qian W, Zhang H, Liang Y, Wu M,
Zhang Y, Zhang X, Gao Q and Li Y: SOX2 is a marker for stem-like
tumor cells in bladder cancer. Stem Cell Reports. 9:429–437. 2017.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4, and Esrrb in bladder, colon, and prostate cancer, and
certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
49
|
Zhang X, Yu H, Yang Y, Zhu R, Bai J, Peng
Z, He Y, Chen L, Chen W, Fang D, et al: SOX2 in gastric carcinoma,
but not Hath1, is related to patients' clinicopathological features
and prognosis. J Gastrointest Surg. 14:1220–1226. 2010. View Article : Google Scholar : PubMed/NCBI
|
50
|
Kim BW, Cho H, Choi CH, Ylaya K, Chung JY,
Kim JH and Hewitt SM: Clinical significance of OCT4 and SOX2
protein expression in cervical cancer. BMC Cancer. 15:10152015.
View Article : Google Scholar : PubMed/NCBI
|
51
|
Zheng S, Pan Y, Wang R, Li Y, Cheng C,
Shen X, Li B, Zheng D, Sun Y and Chen H: SOX2 expression is
associated with FGFR fusion genes and predicts favorable outcome in
lung squamous cell carcinomas. Onco Targets Ther. 8:3009–3016.
2015.PubMed/NCBI
|
52
|
Otsubo T, Akiyama Y, Yanagihara K and
Yuasa Y: SOX2 is frequently downregulated in gastric cancers and
inhibits cell growth through cell-cycle arrest and apoptosis. Br J
Cancer. 98:824–831. 2008. View Article : Google Scholar : PubMed/NCBI
|
53
|
Wang S, Tie J, Wang R, Hu F, Gao L, Wang
W, Wang L, Li Z, Hu S, Tang S, et al: SOX2, a predictor of survival
in gastric cancer, inhibits cell proliferation and metastasis by
regulating PTEN. Cancer Lett. 358:210–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
54
|
Croom E: Metabolism of xenobiotics of
human environments. Prog Mol Biol Transl Sci. 112:31–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
55
|
Burger H, Loos WJ, Eechoute K, Verweij J,
Mathijssen RH and Wiemer EA: Drug transporters of platinum-based
anticancer agents and their clinical significance. Drug Resist
Updat. 14:22–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
56
|
Ballatori N, Hammond CL, Cunningham JB,
Krance SM and Marchan R: Molecular mechanisms of reduced
glutathione transport: Role of the MRP/CFTR/ABCC and OATP/SLC21A
families of membrane proteins. Toxicol Appl Pharmacol. 204:238–255.
2005. View Article : Google Scholar : PubMed/NCBI
|
57
|
El-akawi Z, Abu-hadid M, Perez R, Glavy J,
Zdanowicz J, Creaven PJ and Pendyala L: Altered glutathione
metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer
Lett. 105:5–14. 1996. View Article : Google Scholar : PubMed/NCBI
|
58
|
Smitherman PK, Townsend AJ, Kute TE and
Morrow CS: Role of multidrug resistance protein 2 (MRP2, ABCC2) in
alkylating agent detoxification: MRP2 potentiates glutathione
S-transferase A1-1-mediated resistance to chlorambucil
cytotoxicity. J Pharmacol Exp Ther. 308:260–267. 2004. View Article : Google Scholar : PubMed/NCBI
|
59
|
Theile D, Grebhardt S, Haefeli WE and
Weiss J: Involvement of drug transporters in the synergistic action
of FOLFOX combination chemotherapy. Biochem Pharmacol.
78:1366–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
60
|
Krzyżanowski D, Bartosz G and Grzelak A:
Collateral sensitivity: ABCG2-overexpressing cells are more
vulnerable to oxidative stress. Free Radic Biol Med. 76:47–52.
2014. View Article : Google Scholar : PubMed/NCBI
|
61
|
Brechbuhl HM, Gould N, Kachadourian R,
Riekhof WR, Voelker DR and Day BJ: Glutathione transport is a
unique function of the ATP-binding cassette protein ABCG2. J Biol
Chem. 285:16582–16587. 2010. View Article : Google Scholar : PubMed/NCBI
|